Q2/FY2023 FINANCIAL RESULTS
ENDED SEPTEMBER 30, 2023

from the beginning

Q2/FY2023 FINANCIAL RESULTS ENDED SEPTEMBER 30, 2023

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

I. Q2/FY2023 Consolidated Financial Results FY2023 Revised Forecasts

• Q2/FY2023 FINANCIAL RESULTS：OVERVIEW

• ACCOUNTING TREATMENT OF BUSINESS COMBINATION WITH IVERIC BIO

• Q2/FY2023 FINANCIAL RESULTS

• XTANDI, PADCEV, XOSPATA：BUSINESS UPDATE

• VEOZAH：BUSINESS UPDATE

• IZERVAY：BUSINESS UPDATE

• Q2/FY2023 FINANCIAL RESULTS：COST ITEMS

• FY2023 REVISED FORECAST

II. Initiatives for Sustainable Growth

• INITIATIVES FOR SUSTAINABLE GROWTH：OVERVIEW OF UPDATES

• XTANDI AND STRATEGIC PRODUCTS：KEY EVENTS EXPECTED IN FY2023

• ENFORTUMAB VEDOTIN / PADCEV：EV-302 LATEST DATA

• ZOLBETUXIMAB：LATEST STATUS

• PROGRESS IN FOCUS AREA APPROACH：CURRENT STATUS OF PROJECTS IN CLINICAL TRIAL

• TOWARD ACHIEVEMENT OF CSP2021

• UPCOMING EVENTS

APPENDIX

• Q2/FY2023：REVENUE BY REGION

• Q2/FY2023 ACTUAL：FX RATE

• FY2023 FORECAST：FX RATE & FX SENSITIVITY

• BALANCE SHEET & CASH FLOW HIGHLIGHTS

• CAPITAL ALLOCATION

• ROBUST PIPELINE OF ASTELLAS

• PROGRESS IN OVERALL PIPELINE

• XTANDI AND STRATEGIC PRODUCTS：STATUS UPDATE

• XTANDI AND STRATEGIC PRODUCTS：POTENTIAL PEAK SALES (AS OF OCT 2023)

• ENZALUTAMIDE(1/2)：ANDROGEN RECEPTOR INHIBITOR

• ENZALUTAMIDE(2/2)：PHASE 3 STUDY DATA BY DISEASE STAGE

• ENFORTUMAB VEDOTIN (EV)(1/4)：NECTIN-4 TARGETED ADC OVERALL UC PROGRAM

• ENFORTUMAB VEDOTIN (EV)(2/4)：CLINICAL STUDIES

• ENFORTUMAB VEDOTIN (EV)(3/4)：STUDY DATA BY DISEASE STAGE OF UC

• ENFORTUMAB VEDOTIN (EV)(4/4)：FUTURE OUTLOOK

• GILTERITINIB：FLT3 INHIBITOR

• ZOLBETUXIMAB：ANTI-CLAUDIN 18.2 MONOCLONAL ANTIBODY

• FEZOLINETANT：NK3 RECEPTOR ANTAGONIST

• AVACINCAPTAD PEGOL (ACP)：COMPLEMENT C5 INHIBITOR / PEGYLATED RNA APTAMER

• FOCUS AREA APPROACH：KEY EVENTS EXPECTED IN FY2023

• ON THE FOREFRONT OF HEALTHCARE CHANGE

Questions

• Questions 1

• Questions 2

• Questions 3

• Questions 4

• Questions 5

• Questions 6

• Questions 7

• Questions 8